TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05591300

Intervention type: DIAGNOSTIC_TEST
Intervention: Microparticles research
Description: The absolute count of the total circulating microparticles will be carried out on the patients' plasma using the NanoSight NS300 instrument (Alphatest). Furthermore, the circulating microparticles will be stained with a combination of three monoclonal antibodies (Becton and Dickinson, NJ,USA) to detect microparticles released by the most abundant cell populations in the blood: leukocyte-derived microparticles (CD45+), endothelial-derived microparticles (CD31+), and PLT-derived microparticles (CD31+ CD41a+).

Intervention type: DIAGNOSTIC_TEST
Intervention: Microparticles research
Description: The absolute count of the total circulating microparticles will be carried out on the patients' plasma using the NanoSight NS300 instrument (Alphatest). Furthermore, the circulating microparticles will be stained with a combination of three monoclonal antibodies (Becton and Dickinson, NJ,USA) to detect microparticles released by the most abundant cell populations in the blood: leukocyte-derived microparticles (CD45+), endothelial-derived microparticles (CD31+), and PLT-derived microparticles (CD31+ CD41a+).
Study: NCT06479473

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy to all residual lesions
Description: Patients assigned to chemoimmunotherapy with radiotherapy group would first receive PET-CT and cranial contrasted MRI to ascertain residual lesions. All residual lesions would be irradiated in a hypofractionated manner.
Study: NCT06116591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mPnC candidate
Description: monovalent pneumococcal conjugate candidate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mPnC control
Description: monovalent pneumococcal conjugate control
Study: NCT05014698

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WGS
Description: Whole Genome sequencing
Study: NCT06283095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: expansion palatoplasty
Description: surgical procedure
Study: NCT05952167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive cervical traction protocol
Description: 2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intensive cervical traction protocol - placebo
Description: 2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
Study: NCT05360186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MateRegen® gel (BioRegen)
Description: Modification of Hyaluronic acid structure to 3-dimensional self-cross-linked network structure enables all-dimensional coverage of tissue surface to enhance better healing process. Self-cross-linked HA hydrogels can maintain the biocompatibility and biodegradability that characterize the unmodified material. Moreover, high dynamic viscosity enables continuous indwelling in the uterine cavity. The gel could provide precise regulation, and degradation and absorption time prolonged to 7-14 days post operatively, which completely cover key postoperative healing period (5-7 days), at the highest time of intrauterine adhesion formation.
Study: NCT05351086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR3100
Description: PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR3100
Description: PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR3100
Description: PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (D.H.E 45)
Description: D.H.E. 45 is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. It is supplied as a clear, colorless solution supplied in sterile ampules for IV, intramuscular, or subcutaneous administration containing (per mL) DHE mesylate, USP 1 mg, ethanol, 94% w/w. 6.2% by volume, glycerin 15% by weight, and water for injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo for PUR3100
Description: Each capsule of matching placebo is filled with iSPERSE powder comprised of mannitol, leucine, and sodium chloride. The PUR3100 inhalation powder is administered using the supplied RS01 inhalation device (RS01 UHR2, Plastiape S.p.A.).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo for D.H.E 45
Description: The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo for D.H.E 45
Description: The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.
Study: NCT06479473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemoimmunotherapy
Description: atients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of chemoimmunotherapy followed by consolidative immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Description: atients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of chemoimmunotherapy followed by consolidative immunotherapy
Study: NCT05351086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo for D.H.E 45
Description: The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.
Study: NCT04864080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer game/task
Description: N-back, COGED, PacMan game, Bandit task, Websurf task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health surveys online
Description: Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health surveys online
Description: Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
Study: NCT04900168

Intervention type: DEVICE
Intervention: Intracranial pressure monitoring
Description: An invasive method to monitor the intracranial pressure of patient
Study: NCT05990998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE and 68Ga-FAPI
Description: Each patient receive a single intravenous injection of 68Ga-FAPI or 68Ga-DOTATATE (2-4mCi) , and undergo PET/CT scan at 40-60 min post injection.
Study: NCT05965297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeltaFil
Description: Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using DeltaFil conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (DeltaFil). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Riva Self Cure HV
Description: Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using Riva conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (Riva Self Cure HV). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
Study: NCT06227026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T cells
Description: Anti-CD19 CAR-T cells are autologous T cells, engineered to express an extracellular single chain variable fragment (scFv) derived from a murine anti-human CD19 hybridoma clone FMC63 linked in frame to hinge region derived from human CD8, transmembrane domain derived from Tumor Necrosis Factor Receptor Super Family 19 (TNFRSF19) the transactivation costimulatory domain 4-1BB, and CD3 zeta signaling domain (Miltenyi Biotec Inc). Anti-CD19 CAR-T cells will be cryopreserved in infusible cryomedia for a later infusion. Anti-CD19 CAR-T cells will be administered in 1 to 3 bags. Bag aliquoting, cell content and cryomedia composition will be done according to specifications in the CMC.
Study: NCT05960279

Intervention type: DEVICE
Intervention: MD100
Description: The MD100 (Medfield Diagnostics, Gothenburg, Sweden) consists of 8 antennas and measurement electronics integrated into a single device; rechargeable ion batteries power the instrument. The radiation transmitted from the device equals approximately 1% of the radiation emitted from a mobile phone. The device is non-invasive and small enough that it can be moved around with ease.~The system transmits microwaves with an output of 0.2 milliWatts (mW) for less than 90 seconds. The power absorbed by the body is 100mW/kg which is a factor of 200 less than what is established by the existing safety standard for microwaves. A mobile phone output, by comparison, can be up to 250mW.~The patient's head is placed in the instrument during measurement while the patient is supine. The procedure takes, on average, 5 minutes to perform.
Study: NCT05904548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Ablation
Description: RF ablation for type I atrial flutter under iCMR guidance
Study: NCT05914428

Intervention type: OTHER
Intervention: ALDH2 rs671 mutation
Description: We selected blood samples from sepsis patients from the biological bank of Qilu hospital and tested their genotypes. The intervention group was ALDH2 rs671 mutation patients
Study: NCT05197075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV/COBI FDC
Description: DRV/COBI FDC tablet dispersed in water will be administered orally.
Study: NCT05281393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEPresent
Description: PrEP2Prevent is being done in several phases (parts) to develop and pilot test a PrEP activation, navigation and support intervention for young men who have sex with men (YMSM), trans youth and non-binary youth in Los Angeles. It targets an intervention for these young people where they need it most - on PrEP uptake. PrEP stands for pre-exposure prophylaxis.
Study: NCT04587531

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial Electrotherapy Stimulation
Description: Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cranial Electrotherapy Stimulation
Description: Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
Study: NCT05072990

Intervention type: DRUG
Intervention: Chinese herb medicine
Description: Patients took 200 ml Chinese herb decoction twice a day before breakfast and dinner.
Study: NCT03642795

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients are asked to complete several questionnaires
Study: NCT06032403

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: flexible patient centred consultations
Description: In the intervention group, the set-up will be flexible patient-centred consultations. The first consultation for the participant will be with the doctor and depending on the participant's need, the following consultations can be scheduled as either a doctor- or a nurse consultation. After each consultation, it will be decided in collaboration between the healthcare professionals and the participant whether a nurse or a doctor consultation will be relevant next. The consultations (whether it is with the doctor or nurse) will be centered around the participant's choice of topics by use of an atopic dermatitis dialogue tool developed in the department. Additionally, the nurse consultation will focus on therapeutic patient education (TPE) in atopic dermatitis. The interval between consultations will depend on the participant's need
Study: NCT05777434

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy for Chronic Neck Pain
Description: Conventional physical therapy for Chronic Neck Pain will include hot pack and TENS for pain relief, axial elongtion exercises to correct posture, cervical isometrics and cervical stabilization exercises. After 2 weeks, functional training will be added. Sets and repetitions will be increased progressively.
Study: NCT05921162

Intervention type: BIOLOGICAL
Intervention: Gene Therapy product:vMCO-I
Description: Safety evaluation to monitor long term effects of previously injected vMCO-I in RP patients

Intervention type: BIOLOGICAL
Intervention: Gene Therapy product:vMCO-I
Description: Safety evaluation to monitor long term effects of previously injected vMCO-I in RP patients
Study: NCT05226884

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: Measurement of distance and intermediate visual acuity at variety targeted correction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: Measurement of distance and intermediate visual acuity at variety targeted correction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Defocus Curve
Description: Measurement of a defocus curve
Study: NCT05777434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy for Chronic Neck Pain
Description: Conventional physical therapy for Chronic Neck Pain will include hot pack and TENS for pain relief, axial elongtion exercises to correct posture, cervical isometrics and cervical stabilization exercises. After 2 weeks, functional training will be added. Sets and repetitions will be increased progressively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scapulothoracic Stabilization Exercises
Description: • Scapulothoracic stabilization exercises in addition to conventional physical therapy will include scapular adduction and shoulder external rotation, B/L shoulder extension with scapular retraction, Eccentric scapular retraction, Brügger exercise and Forward punch. Exercises would be given using latex Thera-Band, or acc. to patient strength for mild to moderate resistance. After 2 weeks, functional training will be added. Sets aand repetitions will be increased progressively.
Study: NCT05226884

Intervention type: DIAGNOSTIC_TEST
Intervention: Defocus Curve
Description: Measurement of a defocus curve
Study: NCT05026632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-002 Intravitreal Implant
Description: Implant inserted during vitrectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-002 Intravitreal Implant
Description: Implant inserted during vitrectomy.
Study: NCT06130007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
Description: Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
Study: NCT06086626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Antibiotics selected by the investigator based on the participant's symptoms, in accordance with local standards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Antibiotics selected by the investigator based on the participant's symptoms, in accordance with local standards
Study: NCT04709939

Intervention type: OTHER
Intervention: OPAT
Description: Observation of patients who are discharged from the hospital on OPAT.

Intervention type: OTHER
Intervention: Focus Group
Description: Focus group with infectious disease physicians who prescribe OPAT to patients but were not involved in the study.
Study: NCT04323605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient assistance program for transplant patients (AMA-ALLO) based on a navigation nurse
Description: Integration of a post-transplant navigation nurse starting at the first post-transplant consultation (starting from D100 +/- 10 days post-transplant). Different times for post-transplant telephone monitoring (every week for the first 2 months, then every 15 days for the next 3 months then once a month for 7 months)
Study: NCT05080309

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate oral intake
Description: During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: free water only
Description: Women will have free access to water only
Study: NCT05700708

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiographic assessment
Description: POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin, midodrine, diuretics and domiciliary albumin
Study: NCT04673175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane / Tazobactam Injection
Description: Zerbaxa (ceftolozane/tazobactam) for injection is supplied as a white to yellow sterile powder for reconstitution in single-use vials; each vial contains 1 g ceftolozane (equivalent to 1.147 g of ceftolozane sulfate) and 0.5 g tazobactam (equivalent to 0.537 g of tazobactam sodium).
Study: NCT06337539

Intervention type: DRUG
Intervention: SSRI
Description: Outpatients with a diagnosis of major depression in the Psychiatry Outpatient Clinics will be evaluated for recruitment.~* Recruitment visit: It will be carried out by one of the psychiatrists participating in the study. The patient will be informed about the study and written consent will be requested. Subsequently, the inclusion and exclusion criteria will be reviewed, and all demographic and clinical variables will be collected.~* Baseline visit: One of the psychiatrists will interview the patient and apply the semi-structured clinical interview and the psychopathological evaluation questionnaires. In addition, a blood draw will be performed for serum collection, spectral cytometric analysis of lymphocyte subpopulations and obtaining peripheral blood mononuclear cells (PBMCs).~* Follow-up visit after 3 months of treatment: Clinical variables will be collected and the same procedures will be performed as during the baseline visit. Not in the control group.
Study: NCT05689515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health app
Description: A mobile app provided to participants to assess effectiveness in managing HIV
Study: NCT05648747

Intervention type: OTHER
Intervention: impact of COVID-19 on Health-Seeking Behaviors
Description: The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Italy's government rapidly established diverse public actions, which helped maintain the medical supply. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether pelvic inflammatory disease rates were affected by the COVID-19 pandemic.

Intervention type: OTHER
Intervention: impact of COVID-19 on Health-Seeking Behaviors
Description: The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Italy's government rapidly established diverse public actions, which helped maintain the medical supply. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether pelvic inflammatory disease rates were affected by the COVID-19 pandemic.
Study: NCT06209450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral hernia repair with mesh fixation
Description: Sutured versus suturless mesh fixation
Study: NCT06213636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22-CAR T cells
Description: The intervention in this clinical trial involves a novel approach using CD19/CD22-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/CD22-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/CD22-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/CD22-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses.
Study: NCT05262764

Intervention type: DRUG
Intervention: JARDIANCE®
Description: JARDIANCE®
Study: NCT06003829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinsunatovir
Description: Single dose, to be spit out after tasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinsunatovir
Description: Single dose, to be spit out after tasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinsunatovir
Description: Single dose, to be spit out after tasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinsunatovir
Description: Single dose, to be spit out after tasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinsunatovir
Description: Single dose, to be spit out after tasting

Intervention type: OTHER
Group type: OTHER
Intervention: Bitrex
Description: Single dose, to be spit out after tasting